SciELO - Scientific Electronic Library Online

vol.16 número2Sex, drugs, bugs, and age: rational selection of empirical therapy for outpatient urinary tract infection in an era of extensive antimicrobial resistanceIn vitro study of the effect of a probiotic bacterium Lactobacillus rhamnosus against herpes simplex virus type 1 índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados


Brazilian Journal of Infectious Diseases

versión impresa ISSN 1413-8670


KHANBABAEE, Ghamartaj et al. A survey on pulmonary pathogens and their antibiotic susceptibility among cystic fibrosis patients. Braz J Infect Dis [online]. 2012, vol.16, n.2, pp.122-128. ISSN 1413-8670.

OBJECTIVE:This study was performed to investigate frequency and antimicrobial susceptibility of pulmonary pathogens in cystic fibrosis (CF) patients. METHODS: 129 pediatric patients with CF were enrolled in this cross-sectional study. Microbiological cultures were performed based on sputum or pharyngeal swabs. Antibiotic susceptibilities of the isolated bacteria were determined by the disk diffusion method. RESULTS: The main infecting pathogens were Pseudomonas aeruginosa (38.8%), Klebsiella pneumoniae (11.6%) and Staphyloccus areus (9.3%), respectively. The most active antibiotics included rifampin (91.7% susceptibility), vancomycin (85%) and imipenem (83.5%). Emerging resistance against aminoglycosides was observed. CONCLUSION: Regarding in vitro susceptibility results, cyclic treatment of long-term oral azithromycin and inhaled tobramycin could prophylactically be applied, and during exacerbations, imipenem or ceftazidime in combination with an aminoglycoside such as amikacin could be considered the drugs of choice.

Palabras clave : Cystic fibrosis; Respiratory tract; infections; Products with antimicrobial action.

        · texto en Inglés     · Inglés ( pdf epdf )


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons